⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Revance and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Revance
↗Nashville, TN, USA
Revance is a global aesthetics and skincare company that provides a comprehensive range of science-driven products. Following its acquisition by Crown Laboratories in February 2025, the company rebranded to operate under the unified name 'Revance'.
The company’s portfolio includes the innovative neuromodulator DAXXIFY® (daxibotulinumtoxinA-lanm), the RHA® Collection of dermal fillers (distributed in partnership with Teoxane SA), and the SkinPen® microneedling system. Revance focuses on delivering differentiated, regenerative solutions for both aesthetic and therapeutic applications.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Aesthetics and Therapeutics
SIZE & FINANCIALS
Founded:1999
Ownership:subsidiary
Status:acquired
FUNDING
Total Raised:$155M
Investors:EW Healthcare Partners, Delphi Ventures, Medicis Pharmaceutical
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Neuromodulator, Peptide-assisted delivery
Active Trials:0
Trial Phases:-
FDA Approvals:2
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Crown Laboratories, Inc.
Acquired By:Crown Laboratories, Inc. (2025-02-01)
Key Partnerships:Teoxane SA (Distribution of RHA® Collection), Viatris Inc. (Biosimilar development)
COMPETITION
Position:Challenger
Competitors:Allergan (AbbVie), Galderma, Merz Pharmaceuticals, Evolus, Hugel
LEADERSHIP
Key Executives:
Jeff Bedard - CEO
Scientific Founders:Dan Browne, Michael Dake, MD, Jacob Waugh, MD
LINKS
Website:revance.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Revance. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.